STROBE Statement—checklist of items that should be included in reports of observational studies

Section/item	Item No	Recommendation	Reported on Page Number/Line Number	Reported on Section/Paragraph
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	p. 5/ line 65	Abstract
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	p. 5/ lines 67-70, 79-81	Abstract
Introduction				
Background/ rationale	2	Explain the scientific background and rationale for the investigation being reported	p.6 / lines 87-111	Introduction
Objectives	3	State specific objectives, including any prespecified hypotheses	p.7 / lines 112-116	Introduction
Methods				
Study design	4	Present key elements of study design early in the paper	p.7 / lines 121-122	Material and Mehods /
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	p. 7 / lines 122-123	Material and Methods / Patients
Participants	6	(a) ***Cohort study***—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up ***Case-control study***—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls ***Cross-sectional study***—Give the eligibility criteria, and the sources and methods of selection of participants	p. 7 / lines 124-127 p. 7-8 / lines 138-147	Material and Methods / Patients Material and Methods / Preoperative period
		(b) ***Cohort study***—For matched studies, give matching criteria and number of exposed and unexposed ***Case-control study***—For matched studies, give matching criteria and the number of controls per case	N/A because is a cross-sectional study	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	p. 9/ lines 171-181	Material and Methods / Parameter included
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	p.8 / lines 140-143	Material and Methods / Preoperative period
Bias	9	Describe any efforts to address potential sources of bias	N/A due to easy access to	
Study size	10	Explain how the study size was arrived at	N/A because the study size	
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	N/A due to study design.	

Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	p. 9 / lines 184-195	Material and Methods /
		(b) Describe any methods used to examine subgroups and interactions	p. 9 / lines 189-194	Material and Methods /
		(c) Explain how missing data were addressed	N/A, 100% data	
		(d) ***Cohort study***—If applicable, explain how loss to follow-up was addressed ***Case-control study***—If applicable, explain how matching of cases and controls was addressed ***Cross-sectional study***—If applicable, describe analytical methods taking account of sampling strategy	N/A because follow-up was not analyzed	
		(e) Describe any sensitivity analyses	N/A because of study	
Results				
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	p. 10 / lines 199-204	Results / Applied Therapeutic Method
		(b) Give reasons for non-participation at each stage	N/A due to a study design	
		(c) Consider use of a flow diagram	N/A only one point for	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	p. 10-11 / lines 207-235	Results
		(b) Indicate number of participants with missing data for each variable of interest	N/A due to easy access to	
		(c) ***Cohort study***—Summarise follow-up time (eg, average and total amount)	N/A because it is a	
Outcome data	15*	***Cohort study***—Report numbers of outcome events or summary measures over time	N/A because it is a	
		Case-control study—Report numbers in each exposure category, or summary measures of exposure	N/A because it is a	
		Cross-sectional study—Report numbers of outcome events or summary measures	p. 10-11 / lines 207-235	Results
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	N/A because we did not need to estimate any data	
		(b) Report category boundaries when continuous variables were categorized	N/A because no	
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A because it is not	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	p. 11 / lines 233 - 235	Results
Discussion				
Key results	18	Summarise key results with reference to study objectives	p. 11 / lines 238-249	Discussion
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	p. 13-14 / lines 303-313	Discussion

Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	p. 12 / lines 250-276 p. 13 / lines 287-298	Discussion
Generalisability	21	Discuss the generalisability (external validity) of the study results	p.12-13 / lines 277-281,	Discussion
Other information				
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	p. 14 / 324-325	Funding

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.

Article information: http://dx.doi.org/10.21037/jtd-20-3025
*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version. In this case, the section/paragraph may be used as an alternative reference.